Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Intravenously as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

NCT04780217 is registered in ClinicalTrials.gov with ImmVira Pharma Co. Ltd as lead sponsor.

NCT NCT04780217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04780217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Intravenously as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
Lead sponsor
ImmVira Pharma Co. Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 10, 2021
Completion date
August 31, 2025
Enrollment
42 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, endometrial cancer, hepatocellular carcinoma, nsclc, ovarian cancer, solid tumor